Nom du produit:2-(6-Chloropyridazin-3-yl)-2-phenylacetonitrile
IUPAC Name:2-(6-chloropyridazin-3-yl)-2-phenylacetonitrile
- CAS：73535-73-6
- Formule moléculaire：C12H8ClN3
- Pureté：95%
- Numéro de catalogue：CM275205
- Poids moléculaire：229.67
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:73535-73-6
- Formule moléculaire:C12H8ClN3
- Point de fusion:-
- Code SMILES:N#CC(C1=NN=C(Cl)C=C1)C2=CC=CC=C2
- Densité:
- Numéro de catalogue:CM275205
- Poids moléculaire:229.67
- Point d'ébullition:
- N° Mdl:
- Stockage:
Category Infos
- Pyridazines
- Pyridazine, also known as o-diazobenzene, is a six-membered heterocyclic compound containing two nitrogen heteroatoms in the 1 and 2 positions with a special structure and a wide biological activity. Pyridazine is more and more popular in drug development, and a variety of pyridazine drugs have been developed and marketed. From the perspective of the therapeutic field, pyridazine drug molecules are mainly used for tumor treatment, but also involve in many therapeutic fields such as inflammation, hypertension and cardiovascular disease. With the increase and in-depth of research, pyridazine drugs will play more roles in the treatment of diseases.
Column Infos
- Neflamapimod
- Dementia with Lewy Bodies (DLB) is a rapidly progressive neurodegenerative disorder with a significant aging population and unmet health need. Alterations in p38 mitogen-activated protein kinases (MAPKs) are found to contribute to the neurodegenerative process in Alzheimer's disease (AD) and related dementias.
CervoMed’s Neflamapimod (VX-745) is an oral, brain penetrant, small molecule inhibitor of the protein kinase p38α. It is designed to specifically target the mechanisms that cause dysfunction and degeneration of neurons in the basal forebrain cholinergic system. Neflamapimod has the potential of reversing synaptic dysfunction in the basal forebrain. The positive phase 2a data was published in Nature Communications, Neurology, and JPAD. Neflamapimod was granted Fast Track Designation by the FDA for DLB, and phase 2b enrollment was completed in June, 2024.
Recherche 
+86 21 5895 0110 
